Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma
This is a phase II open label study that is looking at the VRCD combination regimen in
patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start
by combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab.
Chemotherapy cycles will be given as outlined below every 35-days and will continue until
two cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease
progression, or a maximum of 8 cycles.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Investigate the Overall response rate (OR) and Time to disease progression (TTP) using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma as classified by the WHO.
Chadi Nabhan, MD
Oncology Specialists, SC
United States: Institutional Review Board
|Onocology Specialists, S.C||Niles, Illinois 60714|
|Oncology Specialists, S.C||Park Ridge, Illinois 60068|